Track topics on Twitter Track topics that are important to you
Do idiopathic pulmonary fibrosis patients benefit from continued treatment with pirfenidone -- particularly those who experienced meaningful disease progression during treatment? Thorax
Researchers found pirfenidone had an acceptable tolerability profile for the treatment of patients with systemic sclerosis-associated interstitial lung disease and suggested tolerability may improve w...
NICE has published a final appraisal rejecting the expanded use of Roche’s Esbriet (pirfenidone) for the treatment of early idiopathic pulmonary fibrosis (IPF) in the UK. Roche said the decision lea...
NEW YORK, NY -- (Marketwired) -- 06/03/16 -- Kadmon Corporation, LLC today announced that the first patient has been dosed in a Phase 2 clinical trial of KD025, the Company's rho-associated coiled-co...
Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This study was designed to ev...
Pirfenidone is a novel oral anti-fibrotic agent approved for the treatment of idiopathic pulmonary fibrosis (IPF). Since IPF is a chronic and progressive disease most commonly encountered in an older ...
Desmoplasia in human pancreatic cancer (PC) promotes cancer progression and hinders effective drug delivery. The objectives of this study were to characterize a homologous orthotopic model of PC in Sy...
The aim of this study was to evaluate the effect of a new anti-fibrotic agent, pirfenidone (PFD), delivered using polyelectrolyte multilayer films on excisional wound healing. Polyelectrolyte multilay...
Idiopathic pulmonary fibrosis (IPF) is a form of chronic progressive fibrosing interstitial lung disease of unknown origin. Recently, nintedanib and pirfenidone demonstrated efficacy in slowing diseas...